| Attribute |
Value |
| 52 Week Change |
-0.0859375 |
| Address1 |
535 Bourke Street |
| Address2 |
Level 22 |
| All Time High |
7.65 |
| All Time Low |
7.07 |
| Ask |
7.1 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
7,040 |
| Average Daily Volume3 Month |
2,986 |
| Average Volume |
2,986 |
| Average Volume10Days |
7,040 |
| Beta |
0.611 |
| City |
Melbourne |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Australia |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
7.0 |
| Current Ratio |
14.643 |
| Custom Price Alert Confidence |
HIGH |
| Day High |
7.19 |
| Day Low |
7.0 |
| Debt To Equity |
0.13 |
| Display Name |
Clinuvel Pharmaceuticals |
| Dividend Rate |
0.03 |
| Dividend Yield |
0.47 |
| Earnings Growth |
-0.263 |
| Earnings Quarterly Growth |
-0.258 |
| Ebitda |
43,678,492 |
| Ebitda Margins |
0.45356 |
| Enterprise To Ebitda |
2.735 |
| Enterprise To Revenue |
1.241 |
| Enterprise Value |
119,463,008 |
| Eps Trailing Twelve Months |
0.44 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,757,289,600 |
| Exchange |
NGM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Exchange Transfer Date |
2,026-07-20 |
| Fax |
61 3 9660 4909 |
| Fifty Day Average |
6.8976 |
| Fifty Day Average Change |
0.102399826 |
| Fifty Day Average Change Percent |
0.014845718 |
| Fifty Two Week Change Percent |
-8.59375 |
| Fifty Two Week High |
9.0 |
| Fifty Two Week High Change |
-2.0 |
| Fifty Two Week High Change Percent |
-0.22222222 |
| Fifty Two Week Low |
5.98 |
| Fifty Two Week Low Change |
1.02 |
| Fifty Two Week Low Change Percent |
0.17056856 |
| Fifty Two Week Range |
5.98 - 9.0 |
| Financial Currency |
AUD |
| First Trade Date Milliseconds |
1,783,949,400,000 |
| Five Year Avg Dividend Yield |
0.29 |
| Float Shares |
43,647,120 |
| Free Cashflow |
32,198,606 |
| Full Exchange Name |
NasdaqGM |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.89631 |
| Gross Profits |
86,316,680 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0 |
| Held Percent Institutions |
0.0 |
| Implied Shares Outstanding |
50,427,898 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,026-07-20 |
| Ir Website |
http://www.clinuvel.com/en/investors-area |
| Language |
en-US |
| Last Dividend Date |
1,725,840,000 |
| Last Dividend Value |
0.034 |
| Last Fiscal Year End |
1,751,241,600 |
| Long Business Summary |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. |
| Long Name |
Clinuvel Pharmaceuticals Limited American Depositary Shares |
| Market |
us_market |
| Market Cap |
352,995,264 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_6117181 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
32,539,888 |
| Next Fiscal Year End |
1,782,777,600 |
| Non Diluted Market Cap |
354,770,301 |
| Open |
7.04 |
| Operating Cashflow |
40,467,992 |
| Operating Margins |
0.36593 |
| Payout Ratio |
0.0777 |
| Phone |
61 3 9660 4900 |
| Prev Exchange |
PNK |
| Prev Ticker |
CLVLY |
| Previous Close |
7.21 |
| Price Hint |
2 |
| Price To Sales Trailing12 Months |
3.6654954 |
| Profit Margins |
0.33789003 |
| Quick Ratio |
13.982 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.21000004 |
| Regular Market Change Percent |
-2.912622 |
| Regular Market Day High |
7.19 |
| Regular Market Day Low |
7.0 |
| Regular Market Day Range |
7.0 - 7.19 |
| Regular Market Open |
7.04 |
| Regular Market Previous Close |
7.21 |
| Regular Market Price |
7.0 |
| Regular Market Time |
1,784,740,681 |
| Regular Market Volume |
1,747 |
| Return On Assets |
0.10624 |
| Return On Equity |
0.13956 |
| Revenue Growth |
0.036 |
| Revenue Per Share |
1.921 |
| Sand P52 Week Change |
0.18089426 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
50,427,898 |
| Short Name |
Clinuvel Pharmaceuticals Limited American Depositary Shares |
| Source Interval |
15 |
| State |
VIC |
| Symbol |
CUVL |
| Ticker Change Date |
2,026-07-20 |
| Total Cash |
232,999,376 |
| Total Cash Per Share |
4.645 |
| Total Debt |
323,843 |
| Total Revenue |
96,302,200 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.05 |
| Trailing Annual Dividend Yield |
0.0069348128 |
| Trailing Eps |
0.44 |
| Trailing P E |
15.909091 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
7.39515 |
| Two Hundred Day Average Change |
-0.39515018 |
| Two Hundred Day Average Change Percent |
-0.053433694 |
| Type Disp |
Equity |
| Volume |
1,747 |
| Website |
https://www.clinuvel.com |
| Zip |
3,000 |